Efficacy of Deucravacitinib in Moderate to Severe Scalp Psoriasis: Analysis of Complete Clearance of Scalp Disease and Symptoms von Stein Gold, Linda, Blauvelt, Andrew, Kircik, Leon, Napoli, Andrew, Cheng, Chun-Yen, Dyme, Rachel, Balagula, Eugene, Bagel, Jerry, Lebwohl, Mark

Volltext

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Improvement in Scalp-Related Quality of Lif... von Feldman, Steven R., Bagel, Jerry, Hoffmann, Matthias, Napoli, Andrew, Cheng, Chun-Yen, Dyme, Rachel, Balagula, Eugene, Zhong, Yichen, Kempers, Steven E., Griffiths, Christopher E. M.

Volltext

Deucravacitinib, an Oral Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter... von Duffin, Kristina Callis, Griffiths, Christopher E. M., Hoffmann, Matthias, Blauvelt, Andrew, Balagula, Eugene, Napoli, Andrew, Jou, Ying-Ming, Dyme, Rachel, Hala, Virginia, Pinter, Andreas, Lebwohl, Mark

Volltext

Efficacy of Deucravacitinib in Plaque Psoriasis Across a Range of Body Surface Area Involvement: Post hoc Analysis of the Randomized, Double-Blinded, Placebo-Controlled, Phase 3b/4... von Blauvelt, Andrew, Thaçi, Diamant, Pariser, David M., Napoli, Andrew, Balagula, Eugene, Cheng, Chun-Yen, Dyme, Rachel, Stein Gold, Linda, Lebwohl, Mark

Volltext